1. Home
  2. HG vs FOLD Comparison

HG vs FOLD Comparison

Compare HG & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hamilton Insurance Group Ltd. Class B

HG

Hamilton Insurance Group Ltd. Class B

HOLD

Current Price

$28.14

Market Cap

2.8B

Sector

N/A

ML Signal

HOLD

Logo Amicus Therapeutics Inc.

FOLD

Amicus Therapeutics Inc.

HOLD

Current Price

$14.26

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HG
FOLD
Founded
2013
2002
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
3.1B
IPO Year
2023
2007

Fundamental Metrics

Financial Performance
Metric
HG
FOLD
Price
$28.14
$14.26
Analyst Decision
Buy
Buy
Analyst Count
7
8
Target Price
$29.00
$29.43
AVG Volume (30 Days)
434.6K
16.3M
Earning Date
11-04-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
4.19
N/A
Revenue
$2,745,461,000.00
$598,704,000.00
Revenue This Year
$25.41
$21.49
Revenue Next Year
$0.82
$18.42
P/E Ratio
$6.77
N/A
Revenue Growth
21.12
21.28
52 Week Low
$16.80
$5.51
52 Week High
$28.72
$14.36

Technical Indicators

Market Signals
Indicator
HG
FOLD
Relative Strength Index (RSI) 60.58 91.24
Support Level $27.45 $10.64
Resistance Level $28.72 $14.36
Average True Range (ATR) 0.53 0.29
MACD -0.00 0.41
Stochastic Oscillator 73.35 97.84

Price Performance

Historical Comparison
HG
FOLD

About HG Hamilton Insurance Group Ltd. Class B

Hamilton Insurance Group Ltd is a specialty insurance and reinsurance company. It operates globally, with underwriting operations in London, Dublin, Bermuda, and the United States. It operates three principal underwriting platforms (Hamilton Global Specialty, Hamilton Select and Hamilton Re) that are categorized into two reporting business segments: International and Bermuda.

About FOLD Amicus Therapeutics Inc.

Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.

Share on Social Networks: